Nitazoxanide: pharmacokinetics and metabolism in man

被引:2
|
作者
Broekhuysen, J
Stockis, A
Lins, RL
De Graeve, J
Rossignol, JF
机构
[1] SGS Biopharma SA, B-1301 Wavre, Belgium
[2] Univ Liege, Inst Pathol, B-4000 Sart, Belgium
[3] Romark Labs lc, Tampa, FL USA
关键词
nitazoxanide; tizoxanide; metabolism; antiprotozoal; radiocarbon; ADME;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Obiectives: Nitazoxanide (N), a new broad-spectrum parasiticidal agent, is rapidly deacetylated to tizoxanide (T). The objective of the study was to determine if metabolites other than T are present in the plasma and excreted after single dose oral administration of radiocarbon-labelled N in healthy subjects. Methods: Six healthy volunteers received a single 500 mg oral dose of N labelled with 2.92 MBq radiocarbon. The radioactivity in blood, plasma, urine, feces and expired air was monitored at scheduled intervals for up to 10 days. Selected samples were assayed by HPLC for T and submitted to metabolite identification by mass spectrometry. In vitro experiments were also conducted (incubation with animal and human microsomes, deacetylation kinetics). Plasma and bile samples obtained in a patient treated with N for sporozoal infection were also assayed for T. Results: Elimination of radiocarbon occurred both in the urine (31.5% of the dose on average) and in the feces (66.2% on average). T and T-glucuronide contributed 15% of total urine radioactivity. N was found to deacetylate extremely rapidly to T in plasma (half-life of about 6 minutes at 37 degrees C) as well as in presence of liver microsomes. T was the only species obtained by incubation with human microsomes while rat microsomes yielded hydroxylated T in addition. The main species identified in human plasma, urine and bile was T-glucuronide, the identification of which was confirmed by comparison with an authentic sample. No species other than T was detected in feces, indicating intensive intestinal deconjugation, while radioactivity and absorbance detectors showed largely unresolved clusters.
引用
收藏
页码:387 / 394
页数:8
相关论文
共 50 条
  • [31] Cocrystals and alloys of nitazoxanide: enhanced pharmacokinetics
    Suresh, Kuthuru
    Mannava, M. K. Chaitanya
    Nangia, Ashwini
    CHEMICAL COMMUNICATIONS, 2016, 52 (22) : 4223 - 4226
  • [32] PHARMACOKINETICS AND METABOLISM OF ALPHA-ACETYLDIGOXIN IN MAN
    BODEM, G
    WIRTH, K
    GERNAND, E
    DENGLER, HJ
    ARCHIVES INTERNATIONALES DE PHARMACODYNAMIE ET DE THERAPIE, 1974, 208 (01): : 102 - 116
  • [33] PHARMACOKINETICS AND METABOLISM OF OMEPRAZOLE IN ANIMALS AND MAN - AN OVERVIEW
    REGARDH, CG
    GABRIELSSON, M
    HOFFMAN, KJ
    LOFBERG, I
    SKANBERG, I
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1985, 20 : 79 - 94
  • [34] PHARMACOKINETICS - METABOLISM AND RENAL EXCRETION OF QUINOLONES IN MAN
    VREE, TB
    WIJNANDS, WJA
    GUELEN, PJM
    BAARS, AM
    HEKSTER, YA
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1986, 8 (01) : 29 - 34
  • [35] PHARMACOKINETICS AND METABOLISM OF GABAPENTIN IN RAT, DOG AND MAN
    VOLLMER, KO
    VONHODENBERG, A
    KOLLE, EU
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1986, 36-1 (05): : 830 - 839
  • [36] THE EFFECT OF VERAPAMIL ON ANTIPYRINE PHARMACOKINETICS AND METABOLISM IN MAN
    BACH, D
    BLEVINS, R
    KERNER, N
    RUBENFIRE, M
    EDWARDS, DJ
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 (06) : 655 - 659
  • [37] PHARMACOKINETICS AND METABOLISM OF BUMETANIDE IN MAN, DOG AND RAT
    BUSCH, U
    FEDORCAK, A
    HAMMER, R
    JAUCH, R
    KOSS, FW
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1979, 29-1 (02): : 315 - 322
  • [38] REVIEW OF THE PHARMACOKINETICS AND METABOLISM OF ZOMEPIRAC IN MAN AND ANIMALS
    MUSCHEK, LD
    GRINDEL, JM
    JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 20 (04): : 223 - 229
  • [39] PHARMACOKINETICS AND METABOLISM OF DOFETILIDE IN MOUSE, RAT, DOG AND MAN
    SMITH, DA
    RASMUSSEN, HS
    STOPHER, DA
    WALKER, DK
    XENOBIOTICA, 1992, 22 (06) : 709 - 719
  • [40] PHARMACOKINETICS AND METABOLISM OF DIGOXIGENIN-MONO-DIGITOXOSIDE IN MAN
    KUHLMANN, J
    ABSHAGEN, U
    RIETBROCK, N
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1974, 7 (02) : 87 - 94